Graybug Vision (GRAY) Competitors $1.58 +0.02 (+1.28%) As of 07/2/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock GRAY vs. GLYC, ORGS, AEON, OBSV, AEZS, NRBO, CPHI, ADXS, MTNB, and CANFShould you be buying Graybug Vision stock or one of its competitors? The main competitors of Graybug Vision include GlycoMimetics (GLYC), Orgenesis (ORGS), AEON Biopharma (AEON), ObsEva (OBSV), Aeterna Zentaris (AEZS), NeuroBo Pharmaceuticals (NRBO), China Pharma (CPHI), Ayala Pharmaceuticals (ADXS), Matinas Biopharma (MTNB), and Can-Fite BioPharma (CANF). These companies are all part of the "pharmaceutical preparations" industry. Graybug Vision vs. Its Competitors GlycoMimetics Orgenesis AEON Biopharma ObsEva Aeterna Zentaris NeuroBo Pharmaceuticals China Pharma Ayala Pharmaceuticals Matinas Biopharma Can-Fite BioPharma GlycoMimetics (NASDAQ:GLYC) and Graybug Vision (NASDAQ:GRAY) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability. Which has more volatility and risk, GLYC or GRAY? GlycoMimetics has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Does the media refer more to GLYC or GRAY? In the previous week, GlycoMimetics' average media sentiment score of 0.00 equaled Graybug Vision'saverage media sentiment score. Company Overall Sentiment GlycoMimetics Neutral Graybug Vision Neutral Is GLYC or GRAY more profitable? Graybug Vision's return on equity of -77.61% beat GlycoMimetics' return on equity.Company Net Margins Return on Equity Return on Assets GlycoMimeticsN/A -230.74% -177.39% Graybug Vision N/A -77.61%-71.34% Which has preferable earnings & valuation, GLYC or GRAY? Graybug Vision has lower revenue, but higher earnings than GlycoMimetics. GlycoMimetics is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlycoMimetics$10K1,000.25-$37.88M-$0.46-0.34Graybug VisionN/AN/A-$35.60M-$24.23-0.07 Do analysts prefer GLYC or GRAY? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlycoMimetics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Graybug Vision 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals have more ownership in GLYC or GRAY? 75.2% of GlycoMimetics shares are held by institutional investors. Comparatively, 49.9% of Graybug Vision shares are held by institutional investors. 8.7% of GlycoMimetics shares are held by company insiders. Comparatively, 7.9% of Graybug Vision shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryGlycoMimetics beats Graybug Vision on 8 of the 11 factors compared between the two stocks. Get Graybug Vision News Delivered to You Automatically Sign up to receive the latest news and ratings for GRAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRAY vs. The Competition Export to ExcelMetricGraybug VisionPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.48M$813.13M$5.54B$8.95BDividend YieldN/A4.84%5.38%4.08%P/E Ratio-0.911.1027.3820.03Price / SalesN/A217.25422.31120.16Price / CashN/A23.4436.6357.47Price / Book0.956.108.085.67Net Income-$35.60M-$27.81M$3.16B$248.47M7 Day Performance0.64%0.67%2.12%2.90%1 Month Performance-3.66%7.16%4.43%5.75%1 Year Performance-62.91%7.88%35.62%21.36% Graybug Vision Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRAYGraybug VisionN/A$1.58+1.3%N/A-61.1%$2.48MN/A-0.9127High Trading VolumeGLYCGlycoMimetics1.2044 of 5 stars$0.16-6.6%N/A-99.4%$10.00M$10K-0.3450High Trading VolumeORGSOrgenesis1.8796 of 5 stars$1.75+0.3%N/AN/A$8.40M$662K0.00150Gap UpAEONAEON Biopharma3.5078 of 5 stars$0.71+0.1%$360.00+50,747.5%-98.8%$8.00MN/A3.935Positive NewsGap UpOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150AEZSAeterna ZentarisN/A$3.36+1.8%N/A-22.2%$6.02M$2.37M-0.2320NRBONeuroBo PharmaceuticalsN/A$0.67-0.9%N/A-86.1%$5.77MN/A0.0010News CoverageCPHIChina Pharma0.3526 of 5 stars$1.72+2.4%N/A-93.2%$5.61M$4.30M0.00250News CoverageADXSAyala PharmaceuticalsN/A$0.12flatN/A-41.5%$5.13M$3.24M-0.0220Gap UpMTNBMatinas Biopharma0.1629 of 5 stars$0.91+2.9%N/AN/A$4.61M$1.10M-0.1930Positive NewsGap DownCANFCan-Fite BioPharma2.733 of 5 stars$1.06+1.4%$14.00+1,220.8%-57.1%$3.75M$674K-0.598 Related Companies and Tools Related Companies GLYC Competitors ORGS Competitors AEON Competitors OBSV Competitors AEZS Competitors NRBO Competitors CPHI Competitors ADXS Competitors MTNB Competitors CANF Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRAY) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Graybug Vision, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Graybug Vision With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRAY Stock Alerts